Short answer

Steris (STE) filed its Q4 2025 10-Q quarterly report on Feb 6, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $1.5B (up 9.2% year over year) with net income of $193M.

Q4 2025 key financials · XBRL

Revenue: $1.5B; +9.2% YoY · +2.5% QoQ
Net income: $193M; +11.2% YoY · +0.6% QoQ
Operating margin: 18.3%
Gross margin: 43.8%
EPS (diluted): $1.95; +11.4% YoY · +0.0% QoQ

Source: XBRL data from the Steris (STE) Q4 2025 10-Q on SEC EDGAR. USD.

Steris Q4 2025 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

Revenue $1,496.2M Q3 FY2026, up 9.2% YoY from $1,370.6M; nine months revenue $4,347.5M, up 9.3% from $3,979.0M
Operating margin Q3 FY2026 18.2% ($273.2M/$1,496.2M) vs 17.9% YoY ($245.3M/$1,370.6M); nine months margin 18.1% vs 16.3% YoY
Best segment: AST segment Q3 revenues +11.0%, operating margin 45.1% vs 44.8% YoY; worst segment: Healthcare margin down to 24.3% vs 25.3% YoY
Operating cash flow $1,006.0M (+13.4% YoY), free cash flow $737.6M (+25.4% YoY); capital expenditures decreased to $278.8M from $299.2M
Management notes inflation, tariff costs pressure margins; expects benefit from restructuring; sales growth driven by volume and pricing; no updated guidance disclosed

Risk Factors

No new or updated risk factors reported since the fiscal 2025 10-K filed May 29, 2025
Continued risks from product liability and regulatory compliance remain material, including FDA regulations on medical devices
Ongoing market risk from competitive pressures in sterilization and healthcare sectors affecting near-term sales
Exposure to foreign currency fluctuations impacting reported earnings due to international operations
Debt refinancing risk due to upcoming maturities and variable interest rates described in 10-K

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Steris quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.

Start free